VISION study with 177Lu-PSMA-617 has met both primary endpoints, significantly improving overall survival and radiographic progression-free survival in patients with PSMA-positive metastatic castration-resistant prostate cancer
The first interpretable results of the phase III VISION study evaluating the efficacy and safety of 177Lu-PSMA-617, a targeted radioligand therapy in patients with progressive PSMA-positive metastatic ...
read article